All News

The FDA approved Viatris' Gwyn Lo, a once-weekly low-dose estrogen (20 mcg) contraceptive patch, based on phase 3 LUMINOUS data showing a Pearl Index of 4.14 pregnancies per 100 woman-years and strong adhesion (98.7% intact). It's approved for women with BMI under 30; common side effects included application-site irritation and intercycle bleeding. Available later in 2026.

Global third-dose hepatitis B (HepB3) vaccine coverage reached 81.8% in 2023, but persistent gaps in Africa and South Asia threaten WHO elimination goals.

The OVERLORD-MS trial finds rituximab matches ocrelizumab in relapsing multiple sclerosis, with similar MRI control, relapses, and safety.

Experts at the Washington, DC, Pop Health Roundtable discussed delays in ILD diagnosis, multidisciplinary care, antifibrotic therapy, and insurance barriers.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

A new AHA scientific statement defines pediatric cardiogenic shock and proposes a 5-stage classification to guide diagnosis, monitoring, and escalation of care.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

CANN says the revised pilot reflects stakeholder input and aims to address accountability challenges in the more than $100 billion 340B program.

Higher CCI scores, prior infection, and prior prophylactic anti-infective treatment were associated with greater risk of subsequent infection in both cancers.

Lilly opens early access to retatrutide for some patients before FDA approval, following scrutiny over a single earlier compassionate-use case.

The former deputy surgeon general takes over an agency that has lacked permanent leadership since Susan Monarez, PhD, was ousted.

A review argues lung cancer screening should move beyond smoking history to include environmental exposures, family history, and AI-driven risk models.

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

A study of more than 270,000 patients with HF found a U-shaped link between ventricular size and mortality risk.

The accreditation body targets sourcing, testing, and marketing practices, as the FDA advisory panel recommends expanding access to compounded peptides.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Boston heart failure specialists discussed diagnostic gaps, cost barriers to newer therapies, and scalable care models for HFpEF and HFmrEF.

Summer heat may accelerate microplastic exposure, raising concerns about health effects and climate impacts.

GPBCH's podcast series helps employers navigate GLP-1 strategy and oncology care access, pairing data-driven insights with patient literacy tools.

At an AJMC roundtable, Boston clinicians detailed fragmented obesity care access, prior authorization burdens, and looming GLP-1 coverage shifts.

Novartis says it can deliver doses to treatment sites with 5 days of order.

The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction.

The researchers of this study warn a mismatch could deepen care gaps for LGBTQ+ patients in restrictive states.

Chronic skin disorders are psychologically impacting children and adolescents, reinforcing the need for routine mental health screening.

Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.